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Abstract 51 
Pre-clinical models have shown that targeting pancreatic stellate cells with all-trans-retinoic-52 
acid (ATRA) reprograms pancreatic stroma to suppress pancreatic ductal adenocarcinoma 53 
(PDAC) growth. Here, in a phase Ib, dose escalation and expansion, trial for patients with 54 
advanced, unresectable PDAC (n=27), ATRA is re-purposed as a stromal-targeting agent in 55 
combination with gemcitabine-nab-paclitaxel chemotherapy using a two-step adaptive 56 
continual re-assessment method trial design. The maximum tolerated dose (MTD) and 57 
recommended phase 2 dose (RP2D, primary outcome) is the FDA approved dose of 58 
gemcitabine-nab-paclitaxel along-with ATRA (45 mg/m2 orally, days 1-15 / cycle). Dose 59 
limiting toxicity (DLT) is grade 4 thrombocytopenia (n=2). Secondary outcomes show no 60 
detriment to ATRA pharmacokinetics.  . Median overall survival for RP2D treated evaluable 61 
population, is 11.7 months (95%CI 8.6-15.7m, n=15, locally advanced (2) and metastatic 62 
(13)). Exploratory pharmacodynamics studies including changes in diffusion-weighted (DW)-63 
MRI measured apparent diffusion coefficient after one cycle, and, modulation of cycle-64 
specific serum pentraxin 3 levels over various cycles indicate stromal modulation. Baseline 65 
stromal-specific retinoid transport protein (FABP5, CRABP2) expression may be predicitve 66 
of response. Re-purposing ATRA as a stromal-targeting agent with gemcitabine-nab-67 
paclitaxel is safe and tolerable. This combination will be evaluated in a phase II randomized 68 
controlled trial for locally advanced PDAC. Clinical trial numbers: EudraCT: 2015-002662-23; 69 
NCT03307148. Trial acronym: STARPAC. 70 
  71 
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Introduction 72 
Advanced PDAC has a dismal prognosis with modestly effective treatment options. 73 
Desmoplastic stroma and hypo-vascularity, distinctive features of PDAC, impede successful 74 
delivery of chemotherapeutic drugs. Pancreatic stellate cells (PSC), critical components and 75 
instigators of desmoplasia, mediate cancer cell pro-survival and pro-invasive capabilities 76 
through multiple signalling cascades1. This tumour-stroma cross-talk is unlikely to be 77 
blocked effectively by merely targeting a single pathway. Targeting the multi-faceted tumour-78 
promoting cancer-stromal cell interactions (i.e., normalising the desmoplastic stroma) may, 79 
however, enhance the effectiveness of conventional chemotherapy.  80 
 81 
Patients with PDAC display fat-soluble vitamin deficiencies due to impaired biliary and 82 
pancreatic secretions. Although vitamin K deficiency is manifested and treated clinically, the 83 
lack of vitamin A2, which is not recognised clinically, may perpetuate PSC activation. In a 84 
healthy pancreas, PSC store a metabolite [retinoic acid (RA)] of vitamin A (retinol). When 85 
activated, in cancer or inflammation, PSC lose RA stores and assume an activated 86 
myofibroblast phenotype1. Furthermore, RA also is a vital molecule regulating key signalling 87 
pathways guiding embryonic pancreas development3,4; signalling cascades that are hijacked 88 
during pancreatic carcinogenesis.  89 
 90 
Based on these observations, we demonstrated, using various PDAC models, that restoring 91 
RA depots within PSC, using ATRA, limited the desmoplasia and suppressed cancer 92 
growth1,5-7. Furthermore, we established that activated PSC impede the migration of immune 93 
cells, such as CD8+ T-cells, Natural Killer and B-cells, into the immediate PDAC 94 
microenvironment; a process which was reversed by ATRA5. ATRA is an ideal agent to 95 
dampen multiple, amplified, embryonic, context-specific signalling cascades activated in 96 
PDAC7,8. ATRA, but not 9-cis- or 13-cis-retinoic acid, reduces PSC proliferation by G1 cell-97 
cycle arrest with accumulation of lipid droplets, thus restoring their normal physiological role. 98 
Specificity of retinoid (RAR) and rexinoid (RXR) receptor isoforms, distinctly used and 99 
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regulated by various RA, is vital in pancreatic embryogenesis and PSC biology9. Our data 100 
suggest a specific up-regulation of RARβ isoform by ATRA7. This is relevant, since 13-cisRA 101 
has previously been found to be ineffective, in combination with either gemcitabine10 or 102 
Interferon11 in patients with PDAC.  103 
 104 
Since only ATRA is relevant to PSC physiology and embryonic development of the 105 
pancreas, here we re-purpose ATRA as a stromal targeting agent, in combination with one 106 
of the widely used standard-of-care chemotherapy12 in a phase Ib clinical trial. We 107 
demonstrate that ATRA is a stromal targeting by conducting pharmacokinetic and 108 
pharmacodynamic studies to discover specific biomarkers whilst determining recommended 109 
phase 2 dose (RP2D). 110 
 111 
  112 
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Results 113 
Trial design and enrolment 114 
We used an innovative two-step, adaptive, Bayesian continual reassessment method using 115 
five potential dose levels (DL) which appears to have advantages over standard 3+3 and 116 
titeCRM designs in accurately predicting RP2D, based on priors of toxicity data13 (Fig. 1, 117 
Supplementary Fig. 1, Supplementary Table 1). A total of 32 patients were screened to enrol 118 
28 of whom 27 received any treatment from February 2016 to February 2018. Final data 119 
collection cut-off for clinical parameters was 1 April 2019. 120 
 121 
Primary and secondary outcomes 122 
We demonstrated that the FDA/EMEA approved doses of gemcitabine (G, 1000mg/m2 iv), 123 
nab-paclitaxel (nP, 125mg/m2 iv), both on days 1, 8 and 15 of each 28-day cycle (PDAC12), 124 
can be combined safely with the recommended dose of ATRA (for acute promyelocytic 125 
leukaemia, APML14) at 45 mg/m2 orally in two divided doses from days 1-15 of each cycle in 126 
patients with PDAC, resulting in an acceptable toxicity and side-effect profile (Dose Level 5 127 
(DL5), Table 1, Fig. 1,2, Supplementary Tables 1-5). Thus, the primary outcome of 128 
Maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) was dose level 5. 129 
Two patients had dose limiting toxicities of grade 4 thrombocytopaenia (one patient each at 130 
Dose Levels 3 and 5). Amongst secondary outcomes on safety and tolerability, neurotoxicity, 131 
characteristically seen with nab-paclitaxel treatment, appeared to be reduced by ATRA, in 132 
frequency and intensity, an aspect to be explored in larger randomised studies. This feature 133 
was previously reported in the context of lung cancer15, although with no underlying 134 
mechanistic explanation16.  135 
 136 
Furthermore, patients treated at the MTD demonstrated encouraging evidence of response 137 
when assessed by best response of change in the target lesion sum of diameters compared 138 
to baseline (Fig. 2B). Median progression-free survival (PFS) was 6.4m (95%CI, 3.5m- not 139 
reached (NR)) and median overall survival (OS) was 10.9m (95%CI, 8.6m-NR) 140 
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(Supplementary Table 4) in the evaluable population (receiving at least two cycles of this 141 
combination or progressing within the first two cycles, n=15) analysis restricted to pre-142 
specified follow-up for 12 months only for RP2D. Post-hoc analysis of these patients (n=15), 143 
of data beyond 12m, showed that the median OS of 11.7m (95%CI, 8.6-15.7m) for RP2D 144 
may be superior to the reported (8.5m, 95%CI: 7.9-9.5m) for metastatic PDAC in the phase 145 
III clinical trial with gemcitabine-nab-paclitaxel12. Additionally, four of these patients (27%) 146 
went on to have second-line treatment (FOLFIRINOX, FOLFIRI, FOLFOX, 5FU+liposomal 147 
irinotecan (n=1 for each)), which was a lower proportion when compared to the pivotal phase 148 
III trial (38-42%)12. Accepting that this is an early phase I trial, these are promising results.  149 
 150 
ATRA pharmacokinetics 151 
The addition of chemotherapy did not reduce plasma levels of ATRA (Fig. 3A, 152 
Supplementary Fig. 2-3, Supplementary Tables 6-7) when compared to historical data of 153 
single-agent ATRA at similar doses in patients without PDAC17,18. The ATRA regimen at 154 
RP2D (at a dosing and schedule optimised for APML19), resulted in consistent plasma ATRA 155 
concentrations (AUC and Cmax) during successive cycles, strongly suggesting lack of 156 
CYP26 enzyme induction, a key factor limiting continued dosing with ATRA20. Patient 157 
compliance with scheduling was excellent, with better median dose intensities of both 158 
cytotoxic agents than previously reported in the phase III trial for gemcitabine-nab-paclitaxel 159 
(Supplementary Table 5)12.  160 
 161 
Biochemical response and Vitamin A levels 162 
CA19-9 biochemical responses are a reliable predictor of long-term survival in PDAC12,21. 163 
Whilst most patients (14/19 at RP2D) showed significant early and sustained CA19-9 164 
responses, we identified five patients who had a poor CA19-9 response (Fig. 3B-C, 165 
Supplementary Fig. 4). Plasma vitamin A levels for most patients were maintained 166 
throughout all cycles, implying no induction of CYP26 enzyme-mediated clearance. The five 167 
patients who had poor CA19-9 responses exhibited either a lower starting, or a decline in 168 
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levels of plasma vitamin A during course of therapy, which upon linear regression analysis 169 
demonstrated a downward trend as opposed to steady levels for patients with a biochemical 170 
response (Fig. 3D-F, Supplementary Fig. 5). This implies that plasma vitamin A levels could 171 
potentially be a surrogate pharmacodynamic marker as a composite readout of absorption 172 
and metabolism of retinol which is upstream of, and therefore distinct from, ATRA absorption 173 
and metabolism. An added benefit is the convenience of a routine assay in hospital 174 
laboratories. Optimal biological dose (OBD) using vitamin A levels greater than or equal to 175 
1µmol/L and less than or equal to 2.5µmol/L, on a exploratory basis22, was achieved in 67-176 
82% of patients in each of the cycles (cycle 1 (72%, n=18), cycle 2 (82%, n=11), cycle 3 177 
(82%, n=11), cycle 4 (67%, n=9), cycle 5 (75%, n=8) and cycle 6 (67%, n=9) for DL5 178 
patients whom vitamin A levels were available and excluding any patients who had dose 179 
modifications from the point of modification onwards (Supplementary Table 8). These data 180 
led to ATRA dosing, as described in DL5, to be taken forward as RP2D.  181 
 182 
Exploratory biomarkers: DW-MRI 183 
Several potential biomarkers have emerged from this phase I study which might be 184 
employed in future studies. Since repeated biopsies of primary tumours are not practical and 185 
may be ethically demanding, we used an imaging biomarker as a surrogate for stromal 186 
activity. The dense cellular stroma reduces tissue water content. Diffusion-weighted (DW)-187 
MRI allows derivation of an apparent diffusion coefficient (ADC), which reflects extra- and 188 
intra-cellular water mobility23, and can be a robust imaging biomarker for response 189 
assessment in human tumours, if appropriately protocoled for cross-platform analysis 190 
(Supplementary Tables 9-10, Supplementary Fig. 6)24. Hence we evaluated ATRA’s stromal 191 
effect using the true diffusion (D) component of ADC. True diffusion (D) values demonstrated 192 
a consistent increase as early as one month after treatment, indicating stromal modulation, 193 
where there is no change in tumour volume, indicating stromal modulation25, as observed in 194 
our preclinical models7 (Fig. 4A-D).  195 
 196 
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Exploratory biomarkers: tissue assays 197 
The baseline biopsies assessed for retinoic acid transport molecules in cancer and stromal 198 
cell compartments, demonstrated a differential distribution of fatty acid binding protein 5 199 
(FABP5) and cellular retinoic acid binding protein 2 (CRABP2)26, using a well-validated 200 
method to distinguish stromal and epithelial compartments27, such that patients with 201 
increased stromal expression of FABP5 were more likely to achieve disease control (Fig. 4E-202 
G; Supplementary Fig. 7,8, Supplementary Table 11). Thus the stromal expression of 203 
FABP5 can be explored as a potential predictive biomarker.  204 
 205 
Exploratory biomarkers: serum assays 206 
Since we demonstrated previously that pentraxin 3 gene (PTX3) is upregulated in activated 207 
PSC, and can be used as a potential diagnostic biomarker for pancreatic cancer28, we 208 
explored whether serum PTX3 could act as a stromal-response biomarker. An upregulation 209 
of serum PTX3 within five hours of administering ATRA on days 1 and 8 of the first cycle, an 210 
effect lost by day 15, indicated that continuous administration of ATRA may not have a 211 
sustained stromal effect (Fig. 4H, Supplementary Fig. 9). Upregulation of serum PTX3 was 212 
not demonstrable by cycle 6 of the treatment when the median serum PTX3 was at the 213 
upper limit of normal, as seen in healthy subjects, perhaps indicating the maximum duration 214 
of ATRA therapy should be six months (Fig. 4I). Serum PTX3 will be explored further in the 215 
context of a planned randomised controlled trial where comparisons can be made with non-216 
ATRA treated patients. 217 
 218 
  219 
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Discussion 220 
The promising results of this phase I study support stromal normalisation as a valid 221 
approach in chemotherapeutically intractable cancers such as PDAC. We demonstrate that 222 
re-purposing ATRA as a stromal targeting agent, with gemcitabine-nab-paclitaxel, is safe 223 
and tolerable with an exciting potential to enhance delivered chemotherapy dose intensity, 224 
and mitigating some of the expected adverse events, such as neurotoxicity, with evidence of 225 
putative pharmacodynamic readouts. These features are in contrast to recently publicized 226 
negative results of HALO 109-031 trial targeting stroma using pegvorhyaluronidase alfa 227 
(PEGPH20), an agent which potentially increases adverse events29.  228 
 229 
This translation of pre-clinical work to a clinical application, based on clinical observations 230 
and repurposing existing drugs, should be tested in other diseases where stromal 231 
normalisation could impact clinical outcome. Based on the encouraging response and 232 
survival data seen here, the efficacy of this regimen will be evaluated in a phase II 233 
randomised clinical trial in locally advanced PDAC (NCT04241276), incorporating 234 
pharmacodynamic biomarkers for ATRA and stromal targeting, and genomic readouts of 235 
tumoural30 and stromal31 heterogeneity, which may play role in differential response.  236 
  237 
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Methods 238 
Trial design and patient population 239 
STARPAC was an open-label, multicenter, phase Ib study of ATRA administered with 240 
gemcitabine and nab-paclitaxel in patients with locally advanced or metastatic pancreatic 241 
cancer, who had not received prior systemic therapy for their disease. Additional eligibility 242 
criteria included World Health Organisation (WHO) performance status 0 or 1, life 243 
expectancy ≥12 weeks and adequate hematologic and end-organ function within 14 days 244 
prior to the first study treatment. Major exclusion criteria were known brain metastases, pre-245 
existing sensory neuropathy (>grade 1) and serious medical risk factors involving any major 246 
organ systems, or serious psychiatric disorders, which could compromise the patient's safety 247 
or the study data integrity.  248 
 249 
There were two parts to this study. In Part 1, a dose-escalation strategy using the two-step 250 
adaptive Bayesian continual reassessment method (CRM)13 was used to determine the MTD 251 
and the recommended dose to be taken forward in Part 2, a dose expansion phase, to 252 
explore the OBD. OBD initially defined by vitamin A levels between 1.5 and 2.5 μM (both 253 
inclusive) at each cycle was post-trial closure modified to levels of 1 and 2.5 μM (both 254 
inclusive) in line with National Institute of Health’s Office of Dietary Supplements’ 255 
recommended levels22. OBD was estimated at 80% of patients achieving serum vitamin A 256 
levels. 257 
 258 
All patients provided written informed consent. Ethical approval for STARPAC clinical trial; 259 
South Central - Berkshire Research Ethics Committee (REC); 15/SC/0548 dated 13 October 260 
2015 (Supplementary Note 1: Trial Protocol). STARPAC trial was prospectively registered 261 
with EudraCT (2015-002662-23) on 11 June 2015 and clinical trial.gov (NCT03307148) on 262 
11 October 2017. Trial opened to recruitment on 20 January 2016. Three substantial 263 
amendments were made to clinical trial protocol, and details are available on EudraCT. 264 
Permission for post-hoc analysis for data beyond 12 months of study was obtained from 265 
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South Central - Berkshire REC on 24 July 2019. All clinical data were collected on an in-266 
house built electronic Case Report Form (eCRF) designed using ORACLE v11.2.0. The 267 
study was sponsored by Barts Health NHS Trust. The Centre for Experimental Cancer 268 
Medicine (CECM), Barts Cancer Institute, Queen Mary University of London had overall 269 
responsibility for trial management. The Trial Management Group (TMG) was responsible for 270 
day-to-day running of the trial. Safety data was reviewed regularly by the Safety Review 271 
Committee (SRC). 272 
 273 
Statistical analysis 274 
It was expected that a maximum of 24 evaluable patients would be enrolled into Part 1 of the 275 
study based on CRM13. For Part 1, the primary objective was to determine the MTD of the 276 
combination of gemcitabine-nab-paclitaxel and ATRA, measured by the occurrence of DLTs 277 
during the first 28 days of treatment that were attributed as possibly, probably or definitely 278 
related to the study treatment. For Part 2, a sample size of 10 was considered reasonable to 279 
provide indicative data on OBD.  280 
 281 
Secondary endpoints included analyses of PK parameters, response rates, progression-free 282 
survival (PFS), overall survival (OS), and safety. For all time-to-event analyses performed, 283 
patients who did not have an event were right censored: - PFS censored on the last date the 284 
patient was known to be progression-free; OS censored at the date of last contact within 12 285 
months of enrolment into trial. Post-hoc OS analysis was carried out for data beyond 12 286 
months after REC approval to include data as there were exceptional survivors. Survival 287 
endpoints were shown graphically with Kaplan-Meier plots.  288 
 289 
All efficacy analyses were performed on the evaluable population which included all patients 290 
receiving at least two cycles of the combination or progressing within the first two cycles, 291 
regardless of whether they were later found to be ineligible or a protocol violator. Safety 292 
analyses included all patients who received at least one dose of study treatment. The worst 293 
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grade of each adverse event (AE) for each patient during study treatment was reported. 294 
Cumulative dose intensity over the first 6 cycles was calculated as the actual amount of 295 
study drug received over the first 6 cycles divided by the expected amount of study drug 296 
received over the first 6 cycles. The expected amount of study drug was calculated based on 297 
the dose and schedule specified in the study protocol. 298 
 299 
Sample size calculations were performed using the software package PASS version 12.0. All 300 
clinical efficacy endpoints were analyzed using STATA version 13.1. Laboratory data were 301 
analyzed using PRISM (GraphPad Inc) version 8. Statistical tests are described as used. 302 
 303 
Sample storage and traceability 304 
All samples had a valid chain of custody throughout procurement, temporary storage at site, 305 
shipping, and permanent storage at the Barts Pancreas Tissue Bank (BPTB, REC Ref: 306 
13/SC/0592, HTA License number: 12199) and were given to laboratory staff via a traceable 307 
database, in a blinded, anonymized manner. 308 
 309 
Pharmacokinetic assays 310 
ATRA, 9-cis-RA and 13-cis-RA were purchased from Sigma Aldrich (Poole, UK), and ATRA-311 
d5 from Toronto Research Chemicals (North York, Ontario, Canada). Liquid chromatography 312 
mobile phase solvents (water, acetonitrile and formic acid), were Optima grade, purchased 313 
from Fisher Scientific (Loughborough, UK). An analytical method, using LC-MS/MS, was 314 
established for the measurement of all-trans retinoic acid concentrations in plasma. The 315 
method was subject to EMEA validation procedures32. Validation of this method included 316 
precision and accuracy, selectivity, specificity, matrix effects (including hemolytic and 317 
hyperlipidaemic plasma), effect of co-medications, carryover, re-injectability, stability in 318 
whole blood, stability of stock and working solutions and stability assessments in plasma 319 
(24h room temperature, 4 freeze/thaw cycles, and long term frozen storage at both -20˚C 320 
and -80˚C).  321 
STARPAC  Kocher et al 
 
26-Feb-20  Page 14 of 24 
 
 322 
All analyses were done using an AB Sciex 6500 mass spectrometer (Warrington, UK) 323 
equipped with a Nexera 2 LC-system (Shimadzu, MA, USA). Internal standard ATRA-d5 was 324 
added to 10 µL of patient plasma sample. The plasma proteins were precipitated using 325 
acetonitrile, followed by vortexing and centrifugation. Supernatants (150 µL) were 326 
transferred to clean wells in a 96-well plate, followed by the addition of 50 µL water and 327 
vortex mixing. Calibration standards (calibration range 50 to 5000 ng/mL) and QC samples 328 
(100, 300, 800 and 4000 ng/mL) were prepared by the addition of ATRA to blank human 329 
plasma, and then processed in the same manner as patient samples (Supplementary Fig. 2, 330 
Supplementary Table 7). 331 
 332 
The extracts were analyzed by reversed phase chromatography (Acquity BEH C18 UPLC 333 
column, Waters Corp., MA, USA), using gradient elution with acetonitrile and 0.1% formic 334 
acid, at a flow rate 0.4 ml/min, total run duration 10min. This was coupled to the MS/MS 335 
detector, operating in positive ion atmospheric pressure chemical ionization mode. The 336 
MS/MS transitions for ATRA and internal standard ATRA-d5 were m/z 301 > 205 and m/z 337 
306 > 206, respectively. The declustering potential, collision energy and collision exit 338 
potential were; 40V, 20V and 12V, respectively, both for ATRA and ATRA-d5. A minimum of 339 
six quality control samples were included in each LC-MS/MS run. ATRA calibration 340 
standards were prepared in the calibration range 50 to 5000 ng/mL using pooled human 341 
plasma. Standards and samples were assayed in the same manner using the internal 342 
standard ATRA-d5. Quality control samples at 100, 300, 800 and 4000 ng/ml were used to 343 
determine accuracy and precision (Supplementary Fig. 2, Supplementary Table 7).   344 
 345 
Pharmacokinetic data were calculated using Prism software (GraphPad) and validated 346 
against PCModfit software (http://pcmodfit.co.uk/nca.html) with substitution of all ‘below limits 347 
of quantification’ levels of ATRA at zero (range could be zero to 62.5ng/ml). 348 
 349 
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DW-MRI  350 
MRI was performed at two institutions on multivendor platforms (Supplementary Table 9). 351 
Longitudinal studies on the same patient were undertaken on the same scanner. The 352 
protocols were developed to maximize signal-to-noise ratio and minimize ghosting and 353 
distortion using a well-validated test object 33.  354 
 355 
Scans were done at baseline and at day 22-28 after treatment. Test object measurements 356 
for quality-assurance of quantitative metrics were undertaken regularly to ensure quality 357 
control. The coefficient of variation (CV) for Apparent Diffusion Coefficient (ADC) across 358 
multiple time-points was 0.4% and 1.4% (Philips and GE respectively). ADC CV between the 359 
two sites was 3.9%. MRI examinations consisted of DW-MRI of the abdomen and pelvis as 360 
per the protocols below, followed by T1-weighted and T2-weighted imaging in matched 361 
positions. 362 
 363 
Diffusion-weighted MRI Analysis  364 
On the pre- and post-treatment scans, regions-of-interest (ROI) were drawn around the 365 
tumor on the high b-value (b = 800 s/mm2) diffusion-weighted images by a board-certified 366 
radiologist in OsiriX version 9.0. ROIs were then copied onto the corresponding ADC maps 367 
which were generated on a voxel-by-voxel basis from a mono-exponential fit to the data as 368 
described by: S(b) = S(0) exp(-b.ADC).24 369 
 370 
Tissue CRABP2, FABP5 371 
H&E quality control of remaining tissue from diagnostic material by a board-certified 372 
pathologist for histological / cytological confirmation demonstrate that there was either 373 
inadequate tissue (n=7) or only cancer cells without stroma (n=5), to carry further analysis. 374 
Hence formalin-fixed paraffin-embedded (FFPE) sections from 15 patients were dewaxed 375 
and rehydrated, antigen retrieved (0.1M citrate buffer, pH 6, microwave, 20m), blocked (1h, 376 
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RT, 2% bovine serum albumin, 0.02% fish skin gelatin, 10% FBS, 5% goat serum) before 377 
use of primary antibodies at 4ºC overnight, followed by appropriate fluorescent-labelled 378 
secondary antibodies 27. The nuclei were then counterstained with DAPI. Organotypic 379 
sections, from as previous experiments7, were used for positive and negative staining 380 
controls (Supplementary Table 11). Controls were uniformly negative with appropriate 381 
isotype-specific immunoglobulin at matching dilutions.  382 
 383 
Immunofluorescent images were taken using the Zeiss Confocal LSM510 microscope at 20x 384 
magnification, and images were visualized using Zeiss Zen 2.3 software. The green channel 385 
represented either α-SMA or CK; the red channel represented FABP5 or CRABP2. The 386 
intensity of fluorescence in the green/red channel for respective molecules was given a 387 
semi-quantitative value, ranging from negative “-“ through to strongly positive “+++”. There 388 
were 4 categories of fluorescence intensity: -, +, ++, +++. The threshold gain and offset was 389 
set according to the intensity of the green/red channel in the organotypic cultures, and 390 
ensured minimal inter-day variability (Supplementary Fig. 7,8).  391 
 392 
Plasma PTX3  393 
PTX3 levels were quantified with a sandwich ELISA using in-house validated protocol based 394 
on a monoclonal antibody MNB4 (Enzo Life Sciences ALX-804-464-C100) 34 . Plasma PTX3 395 
concentrations were quantified using the sandwich ELISA as follows: 96 well-ELISA plates 396 
were coated with MNB4 anti- human PTX3 antibody (100 ng/well) diluted in coating buffer 397 
(15mM carbonate buffer, pH 9.6, overnight, 4°C), washed, blocked (5% dry milk in washing 398 
buffer, 2h, room temperature), washed and incubated with either 50 μl of diluted plasma (1:3 399 
dilution in PBS without Ca++ Mg++ and 2% BSA) or 50 μl recombinant human PTX3 400 
standards (0.31-20 ng/ml), all in duplicates for 2h at 37°C. After two washes, 50 ng/ml of 401 
biotinylated PTX3 (Enzo Life Sciences, cat. ALX-210-365B) antibody was added in each well 402 
for 1h at RT, washes and color realized by 100 μl/well streptavidin-horseradish peroxidase 403 
(Amersham, cat. RPN4401V) diluted 1:4,000 for 1h at RT. After further washes 100 μl of 404 
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chromogen substrate (ThermoFisher cat. 34028B) was added and plates read after 15min at 405 
450 nm in a plate-reader. Polynomial regression graphs were constructed for standard 406 
curves. Plasma samples of each patient time-point were thawed only once and assayed, 407 
maintaining a chain of custody, in duplicate. ELISA was conducted in a blinded manner, and 408 
inter-day variability standard patient samples were used with CV 0.17 (Supplementary Fig. 409 
9). Patient variables were unblinded after submission of readouts. 410 
 411 
Data availability 412 
The data supporting this Article are available within the Article, Supplementary Information or 413 
available from the authors upon request.  414 
 415 
 416 
 417 
  418 
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Figure Legends 546 
Figure 1. CONSORT diagram for STARPAC clinical trial.  547 
Number of patients at all Dose Levels (DL) in dose-escalation, part 1 (using the STARPAC 548 
adaptive trial design13) for maximum tolerated dose (MTD) estimation, showing Dose limiting 549 
toxicity (DLT) and dose expansion (part 2) of the trial for optimal biological dose (OBD) 550 
estimation leading to recommended phase 2 dose (RP2D).  551 
 552 
Figure 2. Primary and secondary endpoints for STARPAC clinical trial.  553 
a: Swimmer’s plot with color code for different dose levels (DL) and duration (months) on X-554 
axis along with type of disease: locally advanced (LA) and metastatic (M), those who 555 
experienced DLT (*) and disease status (Death (D), progressive disease (PD)) censored at 556 
the pre-specified 12 months of starting on the trial. 557 
b: Waterfall plot of best percentage change of sum of diameters in target lesion from 558 
baseline in RP2D treated patients based on an evaluable population. A positive change 559 
denotes an increase in the target lesion sum of diameters over time and, likewise, a negative 560 
change denotes a decrease in the target lesion sum of diameters over time. Reference lines 561 
added for response (-30% change in target lesion sum of diameters) and progression (20% 562 
change in target lesion sum of diameters). RECIST responses are marked with asterisk (*). 563 
There was progression for 6.7% (95% CI: 0.2-31.9%) and response in 46.7% (95% CI: 21.3-564 
73.4%) of patients.  565 
c: Post-hoc (including data from beyond 12 months) estimated median overall survival in 15 566 
patients receiving RP2D on evaluable population basis. Number of events =13. Kaplan-567 
Meier plot. 568 
 569 
Figure 3: ATRA pharmacokinetics, biochemical CA19-9 response and vitamin A levels. 570 
a: Serum ATRA levels for the first three cycles are summarized as mean (SEM) for the first 571 
five hours after co-administration of ATRA at 45mg/m2 with chemotherapy drugs.  572 
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b: Absolute CA19-9 levels on logarithmic Y-axis for patients on Dose Level 5 at start of each 573 
cycle. Summary statistics represented by box (median ± interquartile range) and whisker 574 
(range: LQR-(1.5xIQR) and UQR+(1.5xIQR)). One-sided Skilling-Mack test, statistic 39.21, p 575 
< 0.001. 576 
c: Normalized CA19-9 levels for each patient on Dose Level 5 with baseline being 100%. 577 
There were 14 biochemical responders (black) compared to 5 non-responders (unique 578 
colors). Responders are defined as those who show >30% reduction of CA19-9 from 579 
baseline with a sustained response (no greater than 20% rise from previous reading at any 580 
time). 581 
d: Vitamin A on Dose Level 5 at start of each cycle. Summary statistics represented by box 582 
(median ± interquartile range) and whisker (range: LQR-(1.5xIQR) and UQR+(1.5xIQR)). 583 
One-sided Skilling-Mack test, statistic 5.95, p = 0.31. 584 
e: Individual values for vitamin A for patients with biochemical non-responders (CA19-9) 585 
highlighted in corresponding colors as in Panel c.  586 
f: Linear regression trend lines comparing biochemical responders (solid line) to non-587 
responders (dashed line) demonstrate that a drop in serum vitamin A levels may indicate 588 
non-responders. N=X R: X is the number of responders at the stated cycle. 589 
N=X NR: X is the number of non-responders at the stated cycle. 590 
 591 
Figure 4: Biomarkers for STARPAC clinical trial 592 
a: MRI sequences as indicated with primary pancreatic tumor (red arrow) and liver 593 
metastasis (white arrow) in T2-weighted images for localization, both lesions demonstrating 594 
change in the apparent diffusion coefficient (ADC) within these tumors, after just one month 595 
of treatment, indicative of an increased mobile water content due to reduction in dense 596 
cellularity with a rim of peripheral restricted tissue represents residual tumor.  597 
Summary statistics of changes in tumor volume (b), ADC values (c), and D values (d) 598 
between pre-treatment (baseline) and post-first-cycle (day 21-28) of treatment. Summary 599 
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data as mean +/- SEM. Data points represent values from individual patients. Two-tailed 600 
Wilcoxon matched-pairs sign-rank test. 601 
e: Representative images of co-immuno-fluorescent images of pancreatic cancer biopsies 602 
prior to commencement of treatment, to assess prevalence of Cellular Retinoic Acid Binding 603 
Protein 2 (CRABP2) and Fatty Acid Binding Protein 5 (FABP5), as indicated with co-staining 604 
with either cytokeratin (CK) or alpha-smooth muscle actin (αSMA) respectively, to 605 
demonstrate a 3+ stain for both CRABP2 and FABP5 in cancer cells and cancer associated 606 
fibroblasts (CAF). Scale bar: 100µm. 607 
f,g: These quantifications (range 0 to 3+) were then assessed for all evaluable biopsies 608 
(n=15) from single representative image using appropriate tissue controls and categorized 609 
according to disease control / progressive disease. Chi-square test. dF = 3 610 
h: Measurement of serum PTX3 by ELISA (GCLP standards, CV 0.17) in patients before 611 
(Base) and five hours after (Post) taking ATRA in the first cycle (C1) on days 1, 8 and 15 612 
i: Measurement of serum PTX3 five hours after taking ATRA on the first day of each cycle 613 
(1-6). Each point represents an individual patient.  614 
h,i: Box (median ± interquartile range) and whisker (full range). Individual measurements per 615 
patient represented as a dot derived from mean of two readings.  Two-tailed Wilcoxon 616 
matched pairs signed rank test.  617 
 618 
 619 
Table 1. Adverse events for STARPAC clinical trial. Distribution of AE. AE ≥ grade 3 and 620 
DLTs in all patients and those receiving DL5 (RP2D) according to SOC term, whether 621 
attributable or not to treatment. *Indicates counts of each instance e.g. if one patient has the 622 
same term three times this is counted as 3 instances. N = Number of patients in the Safety 623 
Set population for the specified group of patients. 624 
 625 
Figure 1. CONSORT diagram for STARPAC clinical trial. 
Number of patients at al Dose Levels (DL) in dose-escalation, part 1 (using the STARPAC adaptive 
trial design13) for maximum tolerated dose (MTD) estimation, showing Dose limiting toxicity (DLT) 
and dose expansion (part 2) of the trial for optimal biological dose (OBD) estimation leading to 
recommended phase 2 dose (RP2D). 
Figure 1
Figure 2. Primary and secondary endpoints for STARPAC clinical trial. 
a: Swimmer’s plot with color code for diferent dose levels (DL) and duration (months) on X-axis along with type of 
disease: localy advanced (LA) and metastatic (M), those who experienced DLT (*) and disease status (Death (D), 
progressive disease (PD) censored at the pre-specified 12 months of starting on the trial.
b: Waterfal plot of best percentage change of sum of diameters in target lesion from baseline in RP2D treated 
patients based on an evaluable population. A positive change denotes an increase in the target lesion sum of 
diameters over time and, likewise, a negative change denotes a decrease in the target lesion sum of diameters over 
time. Reference lines added for response (-30% change in target lesion sum of diameters) and progression (20% 
change in target lesion sum of diameters). RECIST responses are marked with asterisk (*). There was progression 
for 6.7% (95% CI: 0.2-31.9%) and response in 46.7% (95% CI: 21.3-73.4%) of patients. 
c: Post-hoc (including data from beyond 12 months) estimated median overal survival in 15 patients receiving RP2D 
on evaluable population basis. Number of events =13. Kaplan-Meier plot.
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Figure 3: ATRA pharmacokinetics, biochemical CA19-9 response and vitamin A levels.
a: Serum ATRA levels for the first three cycles are summarized as mean (SEM) for the first five hours after co-administration of ATRA
 at 45mg/m2 with chemotherapy drugs. 
b: Absolute CA19-9 levels on logarithmic Y-axis for patients on Dose Level 5 at start of each cycle. Summary statistics represented 
by box (median ± interquartile range) and whisker (range: LQR-(1.5xIQR) and UQR+(1.5xIQR). One-sided Skiling-Mack test, 
statistic 39.21, p < 0.001.
c: Normalized CA19-9 levels for each patient on Dose Level 5 with baseline being 100%. There were 14 biochemical responders 
(black) compared to 5 non-responders (unique colors). Responders are defined as those who show >30% reduction of CA19-9 from 
baseline with a sustained response (no greater than 20% rise from previous reading at any time).
d: Vitamin A on Dose Level 5 at start of each cycle. Summary statistics represented by box (median ± interquartile range) and 
whisker (range: LQR-(1.5xIQR) and UQR+(1.5xIQR). One-sided Skiling-Mack test, statistic 5.95, p = 0.31.
e: Individual values for vitamin A for patients with biochemical non-responders (CA19-9) highlighted in coresponding colors as in 
Panel c. 
f: Linear regression trend lines comparing biochemical responders (solid line) to non-responders (dashed line) demonstrate that a 
drop in serum vitamin A levels may indicate non-responders. 
N=X R: X is the number of responders at the stated cycle.
N=X NR: X is the number of non-responders at the stated cycle.
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Figure 4: Biomarkers for STARPAC clinical trial
a: MRI sequences as indicated with primary pancreatic tumor (red arow) and liver metastasis (white arow) in T2-weighted images 
for localization, both lesions demonstrating change in the apparent difusion coeficient (ADC) within these tumors, after just one 
month of treatment, indicative of an increased mobile water content due to reduction in dense celularity with a rim of peripheral 
restricted tissue represents residual tumor. Summary statistics of changes in tumor volume (b), ADC values (c), and D values (d) 
between pre-treatment (baseline) and post-first-cycle (day 21-28) of treatment. Summary data as mean +/- SEM. Data points 
represent values from individual patients. Two-tailed Wilcoxon matched-pairs sign-rank test.
e: Representative images of co-immuno-fluorescent images of pancreatic cancer biopsies prior to commencement of treatment, to 
assess prevalence of Celular Retinoic Acid Binding Protein 2 (CRABP2) and Faty Acid Binding Protein 5 (FABP5), as indicated 
with co-staining with either cytokeratin (CK) or alpha-smooth muscle actin (αSMA) respectively, to demonstrate a 3+ stain for both 
CRABP2 and FABP5 in cancer cels and cancer associated fibroblasts (CAF). Scale bar: 100µm.
f,g: These quantifications (range 0 to 3+) were then assessed for al evaluable biopsies (n=15) from single representative image 
using appropriate tissue controls and categorized according to disease control / progressive disease. Chi-square test. dF = 3.
h: Measurement of serum PTX3 by ELISA (GCLP standards, CV 0.17) in patients before (Base) and five hours after (Post) taking 
ATRA in the first cycle (C1) on days 1, 8 and 15
i: Measurement of serum PTX3 five hours after taking ATRA on the first day of each cycle (1-6). Each point represents an individual 
patient. h,i: Box (median ± interquartile range) and whisker (ful range). Individual measurements per patient represented as a dot 
derived from mean of two readings. Two-tailed Wilcoxon matched pairs signed rank test. 
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Table 1. Adverse events for STARPAC clinical trial. Distribution of AE. AE ≥ grade 3 and 
DLTs in all patients and those receiving DL5 (RP2D) according to SOC term, whether 
attributable or not to treatment. *Indicates counts of each instance e.g. if one patient has the 
same term three times this is counted as 3 instances. N = Number of patients in the Safety 
Set population for the specified group of patients. 
 
Adverse events (AE) summary 
 
DL5 Patients All Patients
Total patients (N) 19 27 
AEs reported, n 470 638 
Patients with at least one AE, n 19 27 
AEs per patient*, median (range) 23 (8 – 71) 23 (8 – 71) 
≥ Grade 3 AEs* reported, n 33 55 
Patients with at least one ≥ Grade 3 AE, n 11 17 
≥ Grade 3 AEs per patient*, median (range) 3 (1 – 5) 3 (1 – 9) 
 
